Mitofusin 2 Attenuates Adenomyosis Progression by Suppressing Epithelial-Mesenchymal Transition: Evidence From Clinical and Experimental Models
Clinical and Experimental Obstetrics & Gynecology · 04.02.2026 · 53 (2)
DOI: 10.31083/ceog46464 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Obstetrics & Gynecology, online erschienen am 04.02.2026. Verfasst von Xuan Wang und 5 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Hubei Province.
Abstract (Originalsprache)
Background
Adenomyosis involves epithelial-mesenchymal transition (EMT), yet the role of mitochondrial regulator Mitofusin 2 (Mfn2) remains unclear. This study investigated the role of Mfn2 in adenomyosis-related EMT and evaluated its potential as a therapeutic target.
Methods
Mfn2 expression was compared between human adenomyotic and normal endometrial tissues using immunohistochemistry. Transforming growth factor-beta 1 (TGF-β1)-induced EMT was established in Ishikawa cells, and Mfn2 was overexpressed to assess EMT markers using quantitative polymerase chain reaction (qPCR) and Western blot, as well as cell migration and invasion (via scratch and Transwell assays). A neonatal mouse model of tamoxifen-induced adenomyosis received intrauterine lentiviral Mfn2 overexpression. Uterine morphology, fibrosis, and EMT markers were evaluated after 20 days.
Results
Mfn2 was significantly downregulated in adenomyosis (p < 0.05). Overexpression of Mfn2 reversed EMT, evidenced by increased E-cadherin and decreased N-cadherin and Vimentin (p < 0.05), suppressed cell migration and invasion in vitro (p < 0.05), improved uterine morphology (p < 0.05), reduced fibrosis (p < 0.05), and inhibited EMT in vivo.
Conclusion
Mfn2 suppresses EMT in adenomyosis, suggesting its protective role and potential as a therapeutic target.
Förderung
- Natural Science Foundation of Hubei Province
Zitieren
APA
Wang, X., Han, Q., Qin, X., Xu, N., Ding, C., & Ye, H. (2026). Mitofusin 2 Attenuates Adenomyosis Progression by Suppressing Epithelial-Mesenchymal Transition: Evidence From Clinical and Experimental Models. Clinical and Experimental Obstetrics & Gynecology, 53(2). https://doi.org/10.31083/ceog46464
Vancouver
Wang X, Han Q, Qin X, Xu N, Ding C, Ye H. Mitofusin 2 Attenuates Adenomyosis Progression by Suppressing Epithelial-Mesenchymal Transition: Evidence From Clinical and Experimental Models. Clinical and Experimental Obstetrics & Gynecology. 2026;53(2). doi:10.31083/ceog46464
BibTeX
@article{Wang2026,
author = {Wang, Xuan and Han, Qing and Qin, Xin and Xu, Nana and Ding, Chun and Ye, Hong},
title = {Mitofusin 2 Attenuates Adenomyosis Progression by Suppressing Epithelial-Mesenchymal Transition: Evidence From Clinical and Experimental Models},
journal = {Clinical and Experimental Obstetrics & Gynecology},
year = {2026},
volume = {53},
number = {2},
doi = {10.31083/ceog46464}
}
EUVIMED